LLY
42
-12
EOG
47
-3
AIG
56
-6
AMT
26
5
LYB
20
-2
M
40
-3
LUV
61
3
RRC
76
-4
AVY
43
-3
JPM
74
3
MUR
39
-4
AA
56
2
MMM
64
-5
AVGO
73
-4
IFF
41
-6
CNX
63
3
OXY
50
-3
PLD
35
-5
DG
17
3
ADT
82
-4
LLY
42
-12
EOG
47
-3
AIG
56
-6
AMT
26
5
LYB
20
-2
M
40
-3
LUV
61
3
RRC
76
-4
AVY
43
-3
JPM
74
3
MUR
39
-4
AA
56
2
MMM
64
-5
AVGO
73
-4
IFF
41
-6
CNX
63
3
OXY
50
-3
PLD
35
-5
DG
17
3
ADT
82
-4
Financhill
Back

Pacira BioSciences 10K Form

Sell
27

PCRX
Pacira BioSciences

Last Price:
$25.61
Seasonality Move:
0.52%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PCRX News And Ratings

See the #1 stock for the next 7 days that we like better than PCRX

PCRX Financial Statistics

Sales & Book Value

Annual Sales: $701M
Cash Flow: $26.9M
Price / Cash Flow: 7.26
Annual Sales: $17.25
Price / Book: 1.42

Profitability

EPS (TTM): -2.28000
Net Income (TTM): $-103.7M
Gross Margin: $530.5M
Return on Equity: -12.66%
Return on Assets: -6.57%

Pacira BioSciences Earnings Forecast

Key Pacira BioSciences Financial Ratios

  • The Gross Profit Margin over the past 17 years for PCRX is 75.69%.
  • The Selling, General & Administrative Expenses for PCRX have been equal to 41.96% of Gross Profit Margin.
  • The Research & Development expenses have been 11.64% of Revenue.
  • The Net Earning history of PCRX is -14.20% of Total Revenues.
  • Per Share Earnings over the last 17 years have been positive in 8 years.

Pacira BioSciences Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: PCRX
CUSIP: 695127
Website: pacira.com

Debt

Debt-to-Equity Ratio: 0.73
Current Ratio: 2.41
Quick Ratio: 1.9

Price-to-Earnings

Trailing P/E Ratio: 28.52
Forward P/E Ratio: 7.05

PCRX Technical Analysis vs Fundamental Analysis

Sell
27
Pacira BioSciences (PCRX) is a Sell

Is Pacira BioSciences a Buy or a Sell?